Blood-Based Risk Score Could Enable Earlier Lung Cancer Prevention

Researchers have identified a 14-protein blood signature capable of predicting lung cancer risk more than five years before diagnosis, potentially opening the door to a new era of precision cancer prevention.

The study, published in Cell by investigators at The Francis Crick Institute and University College London (UCL), combines large-scale human population data, mechanistic laboratory studies, and clinical trial analyses to demonstrate that a blood-based inflammatory signature can identify individuals at elevated risk of lung cancer and may pinpoint those most likely to benefit from preventive treatment.

The findings move beyond traditional risk models based on age and smoking history and offer what researchers describe as a potential equivalent of cholesterol testing for lung cancer prevention.

Moving beyond smoking-based risk assessment

Current lung cancer screening programs primarily target older individuals with a history of smoking. While smoking remains the leading risk factor, many lung cancers arise in people who would not qualify for screening under existing criteria, including never-smokers and individuals exposed to environmental pollutants.

The research team sought to develop a biologically informed method of identifying risk by focusing on inflammation, which has emerged as a critical driver of tumor development.

Previous work from the group demonstrated that air pollution can promote lung cancer by triggering inflammatory responses that awaken dormant cells carrying cancer-causing mutations. The new study aimed to determine whether this inflammatory state could be detected in the blood before cancer becomes clinically apparent.

Machine learning identifies a 14-protein signature

Using plasma protein measurements from more than 48,000 participants in the UK Biobank, researchers applied machine learning approaches to identify blood proteins associated with future lung cancer diagnoses.

The algorithm incorporated conventional risk factors such as age, smoking status, prior lung disease, and plasma protein profiles. Analysis revealed a panel of 14 circulating proteins that consistently predicted lung cancer risk within five years of diagnosis.

The signature was validated across eight independent international datasets and remained predictive across diverse populations, including a cohort composed entirely of non-smokers.

Individuals who later developed lung cancer consistently exhibited elevated levels of the signature years before their diagnosis.

“This is a proof of concept that, one day, we could use this signature to offer preventive treatment to people at risk of lung cancer,” said Tej Pandya, clinical PhD student at UCL and visiting scientist at The Francis Crick Institute.

Detecting an inflammatory state before cancer emerges

One of the study’s most significant findings is that the signature appears to reflect a pre-cancerous inflammatory environment rather than the presence of an undetected tumor.

The researchers found evidence that the protein profile originates from changes within the lung microenvironment before malignant transformation occurs.

Further analyses showed that the same signature was elevated in individuals who later developed chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis, suggesting it may identify a broader inflammatory state that predisposes individuals to multiple lung diseases.

Studies in mouse models provided additional support for this hypothesis. Exposure to air pollution increased both the protein signature and the abundance of a cellular state known as KAC cells—adaptive cells that emerge during tissue injury but can become malignant when cancer-driving mutations are present.

Mutant cells arising from several distinct lung cell populations converged on this same KAC state during the earliest stages of cancer development.

Linking air pollution, inflammation, and cancer

The findings build on earlier research implicating the inflammatory cytokine interleukin-1 beta (IL-1β) as a critical mediator of pollution-driven lung cancer.

The investigators demonstrated that air pollution exposure increased IL-1β signaling, elevated components of the 14-protein signature, and expanded KAC cell populations.

Blocking IL-1β in mice reduced KAC cell numbers and slowed early tumor formation, providing experimental evidence that inflammatory signaling contributes directly to cancer initiation.

These observations suggest that the blood signature may serve not only as a risk marker but also as a biological indicator of an underlying process that can be therapeutically targeted.

Revisiting a major clinical trial

To determine whether the signature could identify patients most likely to benefit from preventive intervention, the researchers revisited data from the landmark CANTOS trial.

The trial originally evaluated the IL-1β inhibitor canakinumab for cardiovascular disease prevention and unexpectedly reported reduced lung cancer incidence as an exploratory outcome. However, the overall cancer-prevention benefit appeared too modest to justify widespread use of the drug for this purpose.

The new analysis tells a different story.

Researchers examined data from 4,651 CANTOS participants and found that individuals with elevated levels of the 14-protein signature experienced the greatest benefit from canakinumab treatment. In this high-risk subgroup, lung cancer incidence was nearly cut in half.

By restricting treatment to those identified by the biomarker signature, the number needed to treat to prevent one lung cancer case fell to 55, a figure comparable to widely accepted cardiovascular prevention strategies such as statin therapy.

Toward precision cancer prevention

The work represents a shift in how researchers think about cancer prevention.

Rather than treating large populations indiscriminately, the study suggests that molecular biomarkers could identify individuals in a reversible pre-disease state and guide targeted interventions before cancer develops.

“Drugs like statins have transformed the prevention of cardiovascular disease, used to treat individuals with a high low-density lipoprotein (LDL),” said Charlie Swanton, FRCP, PhD, clinical research director at The Francis Crick Institute and professor of cancer at UCL.

“But we don’t yet have an LDL-like marker of risk or a statin for lung cancer.”

Swanton added that identifying an inflammatory state before tumor formation provides a potential “window of opportunity” in which preventive treatment could be most effective.

Implications beyond lung cancer

The investigators note that the inflammatory signature may reflect a broader biological phenomenon associated with aging and chronic disease.

Because the signature was also associated with future COPD and pulmonary fibrosis, it may represent a shared pre-symptomatic inflammatory state that precedes multiple age-related lung disorders.

If validated in prospective studies, the approach could ultimately support routine blood-based risk assessment and targeted prevention strategies not only for lung cancer but potentially for other inflammation-driven diseases.

For now, the findings provide one of the strongest demonstrations yet that cancer risk can be detected years before diagnosis and that those biological signals may be actionable.

The challenge ahead will be determining whether identifying high-risk individuals and intervening early can translate into measurable reductions in lung cancer incidence, a question future prospective prevention trials will seek to answer.

The post Blood-Based Risk Score Could Enable Earlier Lung Cancer Prevention appeared first on Inside Precision Medicine.

Microglial State Shift May Determine Whether Alzheimer’s Disease Pathology Leads to Dementia

Researchers from the VIB-KU Leuven Center for Neuroscience, the UK Dementia Research Institute, and Muna Therapeutics have discovered a biological transition that occurs in Alzheimer’s disease (AD) that may influence whether the accumulation of amyloid-β plaques and tau pathology progresses to dementia. Using human brain tissue from octogenarians with and without dementia as well as cognitively healthy centenarians, the team found that a shift in the behavior of microglia occurs at a critical point between amyloid-driven inflammation and tau-associated neurodegeneration. The research, published in Nature Medicine, point to these microglial transitions as a potential new target for treating the disease.

“This has been an exciting journey with many partners,” said co-senior author Bart De Strooper, MD, PhD, a professor at VIB-KU Leuven Center for Neuroscience, Belgium. “The study, entirely based on human donor material, provides insight into one type of resilience mechanism in the progression of AD to dementia.”

Alzheimer’s disease affects more than 55 million people worldwide, but prior research has not been able to fully explain why some people with AD remain cognitively healthy despite having significant amounts of amyloid plaques and tau tangles in their brains. Current models of AD progression have assumed a linear path from amyloid accumulation to tau pathology, neurodegeneration, and cognitive decline. However, observations of cognitively intact older adults with substantial pathology have indicated there may be other biological factors that influence dementia development.

“AD is not an inevitable outcome of pathology but a dynamic process shaped by how brain cells respond to amyloid-β (Aβ) and tau,” the researchers wrote, adding that “Clinical symptoms may thus arise only when these compensatory mechanisms fail, crossing inflection points that shift the brain from adaptation to degeneration.”

Previous studies using single-cell and spatial transcriptomics had shown that microglia, astrocytes, oligodendrocytes, and neurons undergo stage-specific changes in response to amyloid accumulation. Those findings, combined with observations that some centenarians maintain cognition despite extensive pathology, suggested that immune-cell responses might influence disease outcomes and were the underpinnings of the current research.

To further understand these mechanisms, the investigators examined 24 well-characterized octogenarian brains and 20 brains from cognitively intact centenarians enrolled in the Dutch 100-plus Study. Using spatial transcriptomics, single-nucleus RNA sequencing, and in situ hybridization to tissue from the superior frontal gyrus, the team was able to analyze gene activity at single-cell resolution while preserving the spatial relationships between cells and pathological features in the brain.

Their analysis identified six distinct tissue domains representing a continuum of Alzheimer’s disease progression. Within this “spatial pathological” continuum of AD the researchers found a “key inflection point marked by a shift from Aβ-associated inflammatory changes to tau-associated cellular programs.”

This transition coincided with a significant change in microglial behavior. Early in the disease process, microglia adopted inflammatory states associated with amyloid plaques. Later, they shifted into antigen-presenting states linked to emerging tau pathology. The researchers described these as early and late plaque-induced gene, or PIG, programs.

Data from the study indicated that resilience to disease progression involved different microglial responses in the different groups studied. Octogenarians who accumulated amyloid plaques but remained free of dementia mounted the early inflammatory microglial response but did not progress to the later antigen-presenting state. This compared with cognitively intact centenarians in which the later microglial program was activated, but this activation occurred without the corresponding buildup of tau pathology typically associated with neurodegeneration.

“Resilient individuals showed distinct pathological patterns: octogenarians without dementia lacked late PIGs, whereas centenarians showed late PIG activation that was uncoupled from tau accumulation,” the researchers wrote.

According to the investigators, these findings indicate that resilience to development of dementia in AD is not simply a matter of avoiding pathology, but may depend on how the brain regulates the cellular consequences of AD pathology.

The research also revealed clues about how microglia might be targeted therapeutically. The researchers suggest that preserving beneficial early microglial functions involved in amyloid clearance and synaptic maintenance while preventing chronic antigen-presenting activation associated with tau pathology could help slow disease progression. Potential targets include pathways involving TREM2, CSF1R, and molecules associated with microglial state transitions.

“These findings open new opportunities to target microglial states—especially pathways such as TREM2—and extend resilience rather than simply focusing on plaque removal,” said co-senior author Niels Plath, PhD, chief scientific officer of Muna Therapeutics. “We are excited to continue this journey and understand the causal role of microglial transitions leading to the identification of novel therapeutic approaches to delay or prevent disease progression.”

Continued research will look to determine the causal mechanisms that drive these microglial state transitions and identifying the genetic, immune, or aging-related factors that allow some individuals to remain resilient despite significant Alzheimer’s pathology.

The post Microglial State Shift May Determine Whether Alzheimer’s Disease Pathology Leads to Dementia appeared first on Inside Precision Medicine.

Universal Coronavirus Vaccine Could Provide Protection Against Future Strains

Results from the first human trial of a universal coronavirus vaccine show early promise for a new approach to vaccine design that could protect against a broad range of strains within major virus groups, including strains that have not emerged yet. These findings were published today in the Journal of Infection.  

“Viruses like influenza, coronaviruses, and the Ebola group are evolving continuously and by the time vaccines are rolled out, they may be poorly matched. The current “reactive” vaccine system struggles to keep pace,” said Saul Faust, PhD, professor of pediatric immunity and infection at the University of Southampton and director of the NIHR Southampton Clinical Research Facility, who acted as chief investigator of the clinical trial.

Currently, vaccines contain antigens from specific viral strains that have been detected and predicted to be circulating in humans seasonally. However, because viruses mutate rapidly, the protection these vaccines offer can be limited by the time the vaccines are manufactured and distributed. In contrast, the PanSarbeco vaccine evaluated in this trial is designed to train the immune system to recognize and fend off a broad range of Sarbeco coronaviruses, including the SARS-CoV2 virus responsible for the COVID-19 pandemic.  

“This new class of universal vaccines are future-proofed,” said Faust. “They not only protect against many variants simultaneously, but potentially against related viruses that haven’t yet emerged and spilt over to humans. If we can develop and clinically advance this new class of vaccines before a virus outbreak begins, millions of lives could be saved, lockdowns avoided, and the economy preserved.”

The technology behind this vaccine uses machine learning to design a super antigen that can provide lasting protection against a broad range of viruses within a group, such as the Ebola group or the Sarbeco coronavirus group, even as they continue to mutate and evolve. This approach originated at the University of Cambridge and is currently being developed by DIOSynVax (Digitally Immune Optimised Synthetic Vaccines), a spin-out company established in 2017. 

“We’ve converted vaccine development from being reactive to being future proof. Our vaccines will continue to provide protection against viruses even as they mutate into new strains,” said Jonathan L. Heeney, DVM, PhD, professor of comparative pathology at the University of Cambridge and chief scientific officer of DIOSynVax. “We’ve overcome the problem of traditional vaccines, which have limited protection. It means we can escape the constant cycle of chasing the virus variants circulating in humans and updating the vaccines to try to catch up, like a dog chasing its tail.”

The PanSarbeco vaccine was tested in 39 healthy volunteers between 18 and 50 years old at NIHR research facilities at Southampton and Addenbrookes Hospital. The super antigen is compatible with most vaccine delivery systems; in this study it was delivered as a DNA vaccine using a needle-free delivery system in two doses administered 28 days apart. All four doses tested were well tolerated by the participants, with no significant safety concerns reported. 

While participants developed immune responses to epitopes of sarbecovirus antigens conserved across strains, preliminary measurements of immunogenicity were modest in some participants potentially due to previous immunization with COVID-19 vaccines. Going forward, a larger Phase II trial will assess the vaccine’s ability to induce a strong, broadly protective immune response. 

“The remarkable success of this AI-designed ‘super-antigen’ trial marks a pivotal leap forward in our ability to deliver broad, lasting viral protection,” said Marian Knight, MBChB, DPhil, professor of maternal and child population health at the University of Oxford and scientific director for NIHR Infrastructure.

 

The post Universal Coronavirus Vaccine Could Provide Protection Against Future Strains appeared first on Inside Precision Medicine.

Bio-Techne, Refeyn Partner on Workflow for Bispecific Antibody, Biosimilar Characterization

This week, Bio-Techne, a provider of life science tools, reagents, and diagnostic product, and Refeyn, a pioneer in mass photometry technology, announced the launch of an integrated workflow for characterizing charge and size variants in bispecific antibodies and biosimilars. 

The workflow combines Bio-Techne’s R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system with Refeyn’s TwoMP mass photometry platform. The combined solution makes it possible for researchers to directly correlate charge heterogeneity with molecular weight and aggregation at single‑molecule resolution in four hours.

“Bispecifics are the fastest growing segment within next‑generation antibodies, but they are very difficult to characterize,” said Gerry Mackay, CEO of Refeyn. That difficulty is due to the structural complexity of these molecules. Incomplete characterization can delay development, increase manufacturing risks, and lead to costly late-stage failures. “This approach directly addresses one of the biggest challenges by combining icIEF fractionation with mass photometry. Researchers can now interrogate charge and size variants together in a single workflow,” he said. 

Within the workflow, charge variants are first separated using the MauriceFlex system. They are then analyzed on Refeyn’s TwoMP platform. The system requires a nanogram‑level sample and reveals size distribution and aggregation at single‑molecule resolution. 

Together, the technologies enable direct characterization of aggregation and size within icIEF-resolved charge variants, something which is not accessible with standalone methods. It reduces reliance on multiple tests and supports faster, more efficient process development. 

These capabilities are a boon for customers, according to Will Geist, president of Bio‑Techne’s Protein Sciences Segment. “Enabling deeper characterization with less sample helps them reduce risk, control costs, and make better decisions earlier in development.” 

The post Bio-Techne, Refeyn Partner on Workflow for Bispecific Antibody, Biosimilar Characterization appeared first on GEN – Genetic Engineering and Biotechnology News.

Preferences for Telehealth Physical Activity Participation Among a Cohort of Children and Youth With Disabling Conditions: Cross-Sectional Survey Study

Background: Children with disabling conditions encounter numerous challenges in participating in physical activity within their community. Telehealth has emerged as an ideal method for promoting physical health and wellness, but there is a need to identify optimal implementation strategies. Objective: This study aimed to describe the telehealth physical activity preferences of active children and youth with disabling conditions to rapidly inform the development of a pilot telehealth program that could be delivered nationally. Methods: A cross-sectional survey was conducted among a convenience sample of pediatric members of a community-based wellness program. Questions probed preferences for delivery method; programming frequency, intensity, duration, and type; desired outcomes; technology access and proficiency; and additional needed supports. Of the initial 56 respondents, 4 (7.1%) over the age of 18 years were excluded, leaving 52 (92.9%) for analysis. Outcomes were summarized descriptively. Results: Of 392 wellness program members, 56 (14.3%) responses were gathered. The mean age of the 52 analyzed respondents was 10 (SD 3; range 5-16) years. The sample predominantly comprised male (32/52, 61.5%) and White (34/52, 65.4%) individuals, with autism spectrum disorder and developmental disorder as the most common disability types (22/52, 42.3% each). Social and psychological barriers were the most frequently reported challenges to physical activity participation (36/52, 69.2% and 27/52, 51.9%, respectively). Most respondents reported an ideal exercise dose of 1 to 2 sessions per week of 30 to 45 minutes at a novice or beginner difficulty level. Winter was the preferred season for participation. The 2 most desired delivery formats were live videoconferencing and prerecorded videos. Desired program outcomes included strength improvement, mental health, developing new hobbies and activities, and social connection. Over 90% of respondents (47/52, 90.4%) reported having adequate technology at home to support virtual participation. Conclusions: Optimal telehealth programs for this cohort should be brief and low intensity and offered seasonally, with both live and prerecorded delivery options. Although this preferred dose does not meet US physical activity guidelines, it may represent an appropriate starting point for many inactive children with disabilities. Future research should examine behavior change strategies that motivate children to enroll in these programs and support gradual increases in physical activity over time.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/161cf4295998dde9bae727b0a89aac87" />

Interpretable Machine Learning Framework for Predicting Major Adverse Cardiovascular Events in Rheumatoid Arthritis Using Electronic Health Records: Multicenter Cohort Study

Background: Patients with rheumatoid arthritis (RA) face higher risks of major adverse cardiovascular events than the general population. While machine learning offers powerful predictive capabilities, its clinical adoption is hindered by the “black-box” nature of complex algorithms. Objective: This study aimed to develop interpretable survival models to predict the risk of major adverse cardiovascular events in patients with RA, providing transparent and actionable insights for personalized clinical prognosis management. Methods: Using data from the Taipei Medical University Clinical Research Database (2011-2022) for 2461 patients with RA, machine learning survival models, including random survival forest (RSF), DeepSurv, and Cox-Time, were compared with the traditional Cox proportional hazards model. Performance was evaluated using the C-index and integrated Brier score. Permutation importance and Shapley additive explanations (SHAP) analyses were integrated to provide explainability for individual-level risk predictions. Results: RSF demonstrated superior performance, achieving a C-index of 0.8771 and an integrated Brier score of 0.0775. Permutation importance identified key features, including creatinine, conventional synthetic disease-modifying antirheumatic drugs, C-reactive protein, alanine aminotransferase, and age at RA diagnosis. SHAP analysis further quantified feature-specific effects, revealing both protective and risk-increasing associations between medications and laboratory indicators. Conclusions: RSF outperformed traditional methods, and integrating SHAP enabled transparent, personalized risk interpretation, translating complex models into actionable insights for clinicians. This approach empowers clinicians to identify high-risk individuals and advances precision medicine in rheumatology. Future work should include temporal validation using data from later years and external validation using datasets from other health care systems to further assess model generalizability.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/115a09d66df24197bd81106f047c20aa" />

Influenza Drugs Could Prevent Cognitive Decline in Chronic Viral Infections 

Researchers at Northwestern University have found that a combination of influenza drugs could reduce cognitive impairment and premature aging in people living with chronic infections. In a study published today in the journal Med, the team uncovered a previously unknown mechanism by which viruses like HIV drive cognitive decline over time even when effectively treated. 

“We are not saying yet that people should take flu drugs to prevent cognitive decline,” explains Mohamed Abdel-Mohsen, PhD, associate professor of medicine in the division of infectious diseases at Northwestern University’s Feinberg School of Medicine. “We are saying that our findings open the door to testing whether this drug class, or better next-generation versions, could be repurposed for brain and aging-related complications.”

At least 25% of people living with HIV develop symptoms affecting their memory and thinking, even when the infection is effectively managed using antiretroviral therapy.  Until now, the reason for it remained unclear. 

Abdel-Mohsen’s team analyzed blood samples from more than 100 people in the AIDS Clinical Trials Group, all of which were infected with HIV and taking antiretroviral therapy. Based on clinical testing, the patients were separated in two groups, one having normal cognition and another cognitive impairment. 

Results showed that those who developed cognitive impairment had reduced levels of glycans in their blood. These protective sugar molecules normally keep inflammation under control, but when they are degraded, inflammation becomes chronic and accelerates aging processes. 

The researchers also found that glycan degradation was more pronounced among women in the study. While men saw changes in glycan levels evolve gradually and steadily over time, women experienced an acceleration around menopause. 

“Before menopause, women show a slower loss of anti-inflammatory glycans and slower accumulation of pro-inflammatory glycans compared with men, but around menopause there is a rapid shift toward a more inflammatory glycan profile,” says Abdel-Mohsen.

In human immune cells and mouse models, a combination of two influenza drugs successfully preserved glycans and reduced inflammation, slowing down aging and protecting memory. The treatment was composed of oseltamivir, sold as Tamiflu, and an experimental drug. Both are glycan-based drugs belonging to the sialidase inhibitor drug class, which block an enzyme that the influenza virus relies on to replicate itself. 

In future studies, the researchers will investigate whether glycans can serve as biomarkers of future cognitive decline, which could eventually lead to the development of predictive blood tests The team is also planning to further study and optimize potential treatment strategies based on the influenza drugs to prevent cognitive impairment.

“On the treatment side, we want to do more preclinical work to optimize the approach,” says Abdel-Mohsen. “Although some sialidase inhibitors are already used safely in people for influenza, they have not been tested for this purpose, dose or duration.”

The post Influenza Drugs Could Prevent Cognitive Decline in Chronic Viral Infections  appeared first on Inside Precision Medicine.

A Billion-Dollar Deal, Trial Trouble, Biohub Updates, and Vaccine Research News

In this week’s episode, we start with news that Fulcrum Therapeutics is scrapping its lead pipeline program for sickle cell disease following concerns from the FDA about the drug’s risks and benefits. Also on the docket, news of Eli Lilly’s latest spending. The pharma giant has added its genetic medicines pipeline and capabilities by signing a $1.9 billion agreement with Ascidian Therapeutics to develop RNA exon editors for treating inherited kidney diseases. Next up, updates to an open-source model for binder design and protein function mapping. Finally, on the peer-review front, we dive into some of the latest vaccine research including insights into the mechanisms that cross-reactive T cells use to target multiple viral species in a single family and an improvement to standard polio vaccines.

 

 

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Fulcrum Halts Development of SCD Candidate Pociredir, Sets Strategic Review
By Alex Philippidis and Kevin Davies, PhD, GEN Edge, June 2, 2026

Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases
By Alex Philippidis, GEN Edge, June 3, 2026

 

Biohub Releases Protein Biology World Model to Address Disease
By Fay Lin, PhD, GEN Edge, May 27, 2026

Cross-Reactive T Cells Could Point to Broad Vaccines or Treatments for Measles, Nipah Virus
GEN, June 2, 2026

Experimental Adjuvant Could Strengthen Mucosal Immunity with Injectable Polio Vaccines 
GEN, June 4, 2026

Touching Base Podcast
Hosted by Corinna Singleman, PhD

Behind the Breakthroughs
Hosted by Jonathan D. Grinstein, PhD


Produced with support from:

skpharmteco logo

The post A Billion-Dollar Deal, Trial Trouble, Biohub Updates, and Vaccine Research News appeared first on GEN – Genetic Engineering and Biotechnology News.

Awakening from the Trance

This blog was originally posted by the TLC Foundation for BFRBs

Trichotillomania touches on all levels of human experience, from the neurological to the spiritual. It represents the interactions of brain chemistry, but also habituated physiological responses, sensory processing, behavior patterns, characteristic emotional states, perceptual styles and beliefs, and the sense of interconnectedness with others and the experience of faith. It is more than just a behavior, although it is most apparent when it manifests itself in that way.

Trichotillomania can be treated at all of these levels through different treatment approaches: medication, relaxation and response prevention, behavior modification, hypnotherapy, psychotherapy, cognitive therapy and visualization, group therapy and spiritual practices. The most effective approach will depend on the specific needs and circumstances of each individual at specific times, as well as on the compatibility of the personalities of the treatment provider and patient/participant.

In this article I will present my own view of treatment with a particular focus on how to understand and address the aspect of trance.

“Trance” is not a clinical term, but it is one which most pullers seem to recognize immediately as a significant part of the hair pulling experience: particularly when reading or watching TV. However, I believe that any time one is pulling, one has entered a trance state and that trance states occur with great frequency even at other times. To look at how to make use of this concept I will first describe what I think treatment needs to address.

Trichotillomania as a symptom: My approach is to look at what the behavior of pulling means to a particular person, and what it means about them. I view pulling as a symptom which indicates something about what is going on in that person’s life and can be best understood if we look at the context in which it occurs – both over time (how did it evolve), and ecologically (how does it fit into the network of the person’s relationships, commitments, self-perceptions, experiences of their own body and emotional states, etc.).

Symptoms are an indication of the existence of some other process. Just as a fever may reflect a viral infection, a repetitive behavior reflects an underlying mental activity. The symptom develops in response to the activity and one of its functions is to achieve some control over the consequences of that mental activity. I believe that trichotillomania indicates an attempted solution to a psychological challenge (or opportunity) one is facing in one’s life. However, it is an ineffective solution for two reasons. Firstly, it doesn’t alter the situation which has become challenging, and so the underlying causes remain unchanged. Secondly, by drawing attention onto itself it obscures those underlying causes. It distracts attention from them.

But the behavior, none the less, does have some purpose and utility. It relieves the anxiety of becoming too aware that there are challenges and opportunities which one feels unprepared to confront.

The role of emotions:

The mechanism which could be drawing one’s attention to these challenges and opportunities is the experience of emotional reaction. Emotions serve to amplify our perceptions of situations by making the good seem better and the bad seem worse. In that way, they lead us to focus on what is important to us so that we will take action. Being able to notice and interpret our emotions is something we learn as we grow up. Emotions represent a kind of language for helping us make meaningful choices as we engage with life.

But if these emotions were felt to be too overwhelming – if what they indicated felt too bad to be tolerated because we did not learn how to resolve the situations they drew attention to – then we eliminated them from our emotional vocabulary and we restricted our awareness of them. Now, when those situations reoccur, rather than notice our feelings of hopelessness and helplessness, we may turn to other mechanisms, more basic ones rooted in physical sensations, to occupy ourselves and restore some sense of order to the world.

So, in this model, the behavior of hair pulling is not an indicator of psychological inadequacy, but rather a lack of awareness. It reflects a split between awareness/thoughts and sensations/feelings. It is the result of an unknown mental process, something one has not been able to assimilate into one’s conscious thought, for which no words or language have been developed.

If this could be understood then I believe there would be less justification for feelings of shame connected with Trichotillomania, because Trichotillomania represents an underlying process outside of personal awareness, and thus is not something voluntarily chosen. (It would also answer the following disturbing statement frequently made to hair pullers: “You could stop if you really wanted to.”)

I have so far described how emotional activity and unconscious thoughts affect us in ways which we do not recognize. Despite this lack of recognition, we still need to adjust to them and regulate or organize ourselves. A good example of this is the way in which a fussy baby, if not picked up or fed when it wants to be, learns to get its thumb into its mouth and suck on it. It is finding a way to organize its reactions to its world by retreating into an attitude of self-sufficiency. In this way it solves the problems of the conflict it experiences between the emotions it feels and the lack of a way to take effective action about them in the outside world. It restores order by returning to a sensation-based activity which it has control over. It has learned to retreat into a trance.

The similarities between this example and the experience of hair pulling are striking. So how is Trichotillomania like a trance, exactly?

Trance:

The (Oxford) dictionary defines “trance” in these ways: a suspension of consciousness; a state of mental abstraction from external things; absorption, exaltation, rapture, ecstasy. Going into a trance is turning away from the world, suspending engagement with it, and entering a twilight zone of self-enchantment. The experience is one of being in between states: neither in one’s own mind, nor aware of one’s body. One has turned away, both from the rest of the world and from the rest of oneself.

It is a state in which one doesn’t think about what one feels, and doesn’t act on what one feels. One has turned away from the parts of the self which are concerned with action and purposefulness. In the trance state, a part of the personality takes over which doesn’t care about anything (except the act of pulling) and ignores the existence of time or consequences to one’s actions. It is the opposite of the perfectionist attitude so common to many hair pullers. Becoming entranced in the act of reading, for example, one detaches from the here and now, and allows this part of the personality to “come out”: while the cat’s away, the mouse plays. It is a secure, dependable, magical place in which one can avoid dealing with the stimulation of one’s spontaneous emotional responses to life.

If we look again at the role of emotions as amplifiers of perceptions, we see that what is happening in this state is that one is neither thinking about, nor acting on, what the emotions could be indicating. And as they indicate what is important so that action can be taken, the trance state eliminates the possibility of taking the action required.

How does this detaching process become chronic?

I believe it is the result of repeated experiences of failing to take effective action on what one’s emotions tell one is important. This failure can have many causes, but the result is that these important situations become perceived as challenging and threatening because they are felt as over stimulating. To protect oneself from discomfort, one disassociates from the situation. The part of oneself which perceives or feels what is going on is split off from consciousness. What remains conscious is the part which doesn’t feel and which preserves a sense of order and calm. Gradually, a gap develops between this external presentation of the self – as coherent, caring, positive – and an inner state of feeling confused, frustrated, and overwhelmed.

A false self develops, a self which appears to be more in control than is actually felt, and which one tries to believe in. The fear of having this façade penetrated adds greatly to the level of stress felt by hair pullers. Because this false self cannot be dropped when one’s gut reactions tell one to, one becomes trapped in a vicious circle that leaves one over stimulated (including the times when one merely seems to be bored), detaching from one’s body, and trying to regain control. A strong need is felt to reconnect to the body and feel grounded.‍

Trichotillomania as a return to the body:

The route to feeling in one’s body again is through becoming hyperaware and hypersensitive to sensation. This is a more basic and elementary experience of oneself: one cannot think or feel what is happening, so one uses a physical behavior to establish a link between unconscious inner experience and being in the real, physical world. This provides a solution to the twilight state of feeling detached. The sensation-focused behavior provides a substitute sense of being connected, and its ritualistic aspect creates a sense of soothing order rather than chaos.

So, looked at in this way, the act of pulling a hair actually represents the second stage of entering into a trance. The trance is triggered by the habitual reaction of disassociating rather than facing a situation which one perceives as overwhelming. But while an attitude of order and calm is being adopted (a state of “mental abstraction”), the experience of being detached from the feelings in the body becomes disorienting and the urgent need is felt to focus on the sensation of touching, playing with, and pulling hair. This provides the experience of concreteness and connectedness which allows the trance to continue.

Awakening:

What is needed is a process for regaining consciousness and turning back to engaging with life. How does one wake up? How can one build a sort of observational platform from which to watch the process of entering into a trance; one which can be separate from the process itself? I would suggest that rather than start with the ultimate goal of avoiding trance states altogether (which may be unreachable), a more pragmatic approach would be to learn how to wake up once one starts.

When we drive long distances on freeways and our attention wanders, we sometimes find ourselves drifting over into the next lane. If there were raised lane markers on the road, they would then alert us by causing a noise and a vibration as the car drove over them. That is the kind of alarm system we are looking for. It doesn’t prevent our minds from wandering, but it brings us back to the here-and-now experience before we get into trouble.

Such a system does exist: it is the sensation of a hair being pulled out. Once one hair is pulled, the opportunity exists to break the trance. That hair can be a signal to come back to the here and now rather than getting into the trouble of starting a pulling binge. (The goal of stopping at one hair pulled would also very likely include the benefit of making it much easier to commit to a realistic process of bringing the behavior within tolerable limits.)

How can one learn to stop at just one? Setting such a goal becomes much more possible if one understands one’s reasons for avoiding the goal until now. I have discussed in this article how Trichotillomania is a process which provides an attempted solution to an underlying tension. There is an inevitable anxiety about relinquishing a familiar, dependable behavior. A part of oneself therefore resists changing it and depends on the benefits it brings. This part has no intention of allowing any changes to occur unless one is prepared for the emotional experiences that follow, and it protects one from them.

A way to understand this resistance to change would be to think of the patterns of our behavior as a balanced mobile hanging from the ceiling. All its parts are interconnected and form a stable pattern. If we remove one of the parts, all of the others start to swing wildly until they settle into a new, substantially different formation. The intermediate stage of unbalanced, indeterminate movement could be likened to the feeling of overstimulation from one’s emotions when the ritualistic trance is denied.

To prepare for this change, an expanded awareness of emotional experience and what it teaches is indispensable. The remainder of this article offers some suggestions for work that can be done alone to expand this ability. This task is made much easier and more effective, however, when it is done in the context of a healing dialogue: either in individual or group therapy, or in a support group. This option deserves serious consideration because the act of communicating to another person helps bring one’s inner experiences into focus. Additionally, when there is the trust that the other person is willing not only to listen but to actively attempt to grasp what the speaker means from the speaker’s own point of view, the feeling of validation and recognition received makes awareness of the emotional states more bearable.

Reading the signals:

Part of the personal preparation which can be done is to establish intent to learn from what is found when one tries to read the signals. This would require a willingness to recognize that there are good reasons for what one feels rather than prejudging emotions as wrong, inappropriate, or proof of all the “bad” things one has come to believe about oneself. It also requires a willingness to feel discomfort, hurt, and vulnerability so that there can be a return to wholeness and the sense of being fully alive.

1. The most direct step is simply to ask yourself questions such as: What am I feeling? What is on my mind? Is something bothering me? What do I want right now? Is there something I should be doing? Special attention should be paid to the first answer that comes to mind, even if it very quickly disappears or seems insignificant. You should have an open mind and be prepared to be surprised. Before asking yourself these questions, stop the activity you are doing, if possible. If answers do not emerge the following techniques can be tried.

2. Let your body speak. Allow yourself to become aware of where you feel tension or discomfort. Imagine that that part of you has a voice and can answer the questions in Step One. Try asking follow-up questions to learn more.

3. Try exaggerating the physical state that you are in. That is, whatever movement your body is making or would like to make, take it to an extreme as if you were a very melodramatic actor or dancer who had no inhibitions. Again, think about how your body is expressing answers to the questions in Step One.

4. Visualize yourself as a child of about five and ask the questions of her or him. The answers should seem to be in the language of a 5-year-old. It might help to hold an object such as a cushion or stuffed animal to you as you try to make contact with yourself in this way. It also might help to combine this with some exaggeration of body expression. Additional questions you might ask could be: What do you need from me? Is somebody upsetting you? (See Reference 1.)

5. Write a question to the child, then switch your pen to your other hand and write the answer with that hand. You should write very quickly and with no attempt to make the writing more legible. Then switch your pen back to your original hand for a further question. Continue the dialogue, and the switching of hands, until no further clarification is necessary. The purpose of this technique is to facilitate the spontaneous flow of ideas. (See Reference 2.)

6. Write out the questions as complete sentences to be completed and complete the same question five times as quickly as possible. The questions would be rewritten as follows: Right now, I want….; or: I am upset because…. Allow any response to come forward. Often, a few unrevealing responses will be followed by one unexpected and more valuable one. (See Reference 3.)

7. Hold the hair which has just been pulled out and ask yourself: What did this hair give itself up for? A significant reason for the failure to stop hair pulling is the frequent presence of trance states, which enable one to deny the consequences of the behavior. Additionally, the experience of trance encourages one to focus on physical sensations such as the feeling of a hair being pulled, so as to achieve a greater sense of being connected to reality.

I have described how one enters a trance when certain situations trigger a habituated expectation of becoming overwhelmed. In self-defense one suspends consciousness of the challenge and retreats into a state of emotional detachment. The alternative to the trance, then, is to identify and assimilate the emotional cues about the situation so that appropriate action can be taken. The sensation of the first hair being pulled can serve as an alarm to awaken one from the trance and begin this process of self-evaluation and a return to an alert engagement with life.

Reference 1: Margaret Paul. Inner Bonding. San Francisco: Harper Collins, 1990.Reference 2: Lucia Cappachione. The Power of Your Other Hand. North Hollywood, CA: Newcastle Publishing, 1988.Reference 3: Nathaniel Branden. How to Raise Your Self-Esteem. New York: Bantam, 1987.

The post Awakening from the Trance appeared first on International OCD Foundation.

Opinion: If Americans risk their lives fighting Ebola overseas, they deserve the right to come home

When I deployed to Sierra Leone during the 2014-2016 West Africa Ebola epidemic, I understood the risks.

Every physician, nurse, epidemiologist, laboratorian, and aid worker who enters an Ebola outbreak does. We know that despite rigorous training and infection prevention measures, exposures can occur. We know that outbreaks unfold in difficult environments, often amid insecurity, fragile health systems, and limited resources. We know that if we become ill, our lives may depend on access to highly specialized medical care.

Read the rest…